Pharmaceuticals News and Research

RSS

UC Davis researchers awarded $15.5 million to develop world's first total-body PET scanner

A UC Davis research team has been awarded $15.5 million to build the world's first total-body positron emission tomography (PET) scanner, which could fundamentally change the way cancers are tracked and treated and put the university on the nation's leading edge of molecular imaging.

7 Oct 2015

Provepep synthesizes bioactive homodimer form of IL-10 using SEA peptide ligation technology

Provepep, the peptide business unit of Provence Technologies Group, a specialist fine chemistry research group, today announces that it has successfully synthesized tens of mg of bioactive homodimer form of IL-10.

7 Oct 2015

OLFUS study supports safety, efficacy of DBV's Viaskin Peanut patch in children with peanut allergy

DBV Technologies, a clinical-stage specialty biopharmaceutical company, today announced that topline findings from the first 12 months of the OLFUS-VIPES study, or OLFUS, support the long-term safety and efficacy of Viaskin Peanut for the treatment of peanut allergy.

7 Oct 2015

Binghamton University biochemist finds new way to fight cancer

A Binghamton University biochemist has discovered a new way to fight cancer, one that attacks only the cancer cells and promises fewer side effects. He hunts hedgehogs.

7 Oct 2015

Researchers find link between El Niño and dengue epidemics

Epidemics of dengue are linked to high temperatures brought by the El Niño weather phenomenon, a University of Florida scientist working with an international team of researchers has found.

7 Oct 2015

Tarix Orphan's TXA127 granted FDA Fast Track Designation for treatment of DMD patients

Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation to TXA127 (angiotensin 1-7) to reduce skeletal muscle damage and fibrosis and thereby improve muscle strength in Duchenne Muscular Dystrophy (DMD) patients.

6 Oct 2015

First patients screened in Axovant's phase 3 study of RVT-101

Axovant Sciences Ltd., a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory global phase 3 study of Axovant's lead product candidate, RVT-101. Axovant also announced that the company and the U.S. Food and Drug Administration have agreed to a Special Protocol Assessment (SPA) supporting this phase 3 program.

6 Oct 2015

AcelRx Pharmaceuticals initiates ARX-04 Phase 3 study in emergency room patients with acute pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute and breakthrough pain, today announced the initiation of an open-label Phase 3 study (SAP302) of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury.

6 Oct 2015

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

Sandoz, a Novartis company and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for its proposed biosimilar to Amgen’s US-licensed Enbrel (etanercept) - a tumor necrosis factor alpha (TNF-α) inhibitor

5 Oct 2015

Calcitonin-gene related peptide antibody inhibition shows migraine prevention promise

TEV-48125, a monoclonal anti-calcitonin-gene related peptide antibody, is well tolerated and effective in the prevention of high-frequency episodic migraine and chronic migraine, findings from two phase IIb studies show.

2 Oct 2015

Tris Pharma announces launch of generic TUSSIONEX

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced the launch of Tris-labeled generic TUSSIONEX, an extended-release suspension containing hydrocodone polistirex and chlorpheniramine polistirex.

1 Oct 2015

Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

Allergan plc, a leading global pharmaceutical company, today announced that the company has received approval from the U.S. Food and Drug Administration to market JUVEDERM ULTRA XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVEDERM ULTRA XC instantly adds fullness to the lips and is the only dermal filler that has proven results lasting up to one year for lip augmentation.

1 Oct 2015

OSU researchers develop new approach to treat eczema

Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.

1 Oct 2015

Beckman Coulter Life Sciences launches QbD1200 Total Organic Carbon (TOC) Analyzer

Beckman Coulter Life Sciences has launched the QbD1200 Total Organic Carbon (TOC) Analyzer.

From Beckman Coulter Life Sciences - Particle Counting and Characterization 1 Oct 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

Unlocking the genes behind antibiotic resistance: an interview with Professor Romesberg

Bacteria are very, very diverse. This is why their susceptibility to different antibiotics can be very different. It also makes the tools they have to evolve resistance in many cases different.

30 Sep 2015

OncoGenex meets target enrollment in apatorsen Phase 2 trial

OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.

30 Sep 2015

BiondVax to begin Phase IIb clinical trial of universal influenza vaccine in Europe

BiondVax Pharmaceuticals Ltd. announced today that it received regulatory clearance from the Hungarian Regulatory Authority (National Institute of Pharmacology and Nutrition, OGYEI) and the Central Ethics Committee in Budapest to initiate a Phase IIb clinical trial. The initiation meeting was scheduled for today, September 30, 2015, together with the partners from the UNISEC European Consortium.

30 Sep 2015

AMO Pharma raises $25 million in private equity financing

AMO Pharma Limited, a privately held biopharmaceutical company focusing on debilitating diseases with limited or no treatment options, announced today that the company has raised $25 million in private equity financing from Woodford Investment Management.

30 Sep 2015

Study raises hope for reducing life-threatening respiratory problems in infants

St. Jude Children's Research Hospital scientists have a lead on reducing life-threatening respiratory problems in infants born to women who develop the liver disorder intrahepatic cholestasis of pregnancy (ICP).

30 Sep 2015

Pharmaceuticals News and Research

UC Davis researchers awarded $15.5 million to develop world's first total-body PET scanner

Provepep synthesizes bioactive homodimer form of IL-10 using SEA peptide ligation technology

OLFUS study supports safety, efficacy of DBV's Viaskin Peanut patch in children with peanut allergy

Binghamton University biochemist finds new way to fight cancer

Researchers find link between El Niño and dengue epidemics

Tarix Orphan's TXA127 granted FDA Fast Track Designation for treatment of DMD patients

First patients screened in Axovant's phase 3 study of RVT-101

AcelRx Pharmaceuticals initiates ARX-04 Phase 3 study in emergency room patients with acute pain

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

Calcitonin-gene related peptide antibody inhibition shows migraine prevention promise

Tris Pharma announces launch of generic TUSSIONEX

Allergan receives FDA approval to market JUVEDERM ULTRA XC for use in lips

OSU researchers develop new approach to treat eczema

Beckman Coulter Life Sciences launches QbD1200 Total Organic Carbon (TOC) Analyzer

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Unlocking the genes behind antibiotic resistance: an interview with Professor Romesberg

OncoGenex meets target enrollment in apatorsen Phase 2 trial

BiondVax to begin Phase IIb clinical trial of universal influenza vaccine in Europe

AMO Pharma raises $25 million in private equity financing

Study raises hope for reducing life-threatening respiratory problems in infants

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring